Why the study?
The VAC/IE chemotherapy regimen for Extra-osseous Ewing's sarcoma/primitive neuroectodermal tumor carries cardiotoxic risks, and cancer therapy-related myocarditis is a potentially threatening side effect requiring accurate diagnosis and management.
Does intravenous immunoglobulin (IVIG) improve left ventricular ejection fraction in a young female with cancer therapy-related myocarditis?
Does intravenous immunoglobulin (IVIG) improve left ventricular ejection fraction in a young female with cancer therapy-related myocarditis?
Intravenous immunoglobulin (IVIG) may be an effective treatment for reversing cancer therapy-related myocarditis and improving left ventricular function in young patients.
Answers are grounded in this paper and cite their sources.
Should not change practice for cancer therapy-related myocarditis; leaves open a potential IVIG role pending controlled trials.
BACKGROUND: The treatment of choice for Extra-osseous Ewing's sarcoma/primitive neuroectodermal tumor (ES/PNET), a rare neoplasm, is the VAC/IE regimen. This regimen includes Doxorubicin, Vincristine, Cyclophosphamide, Ifosfamide, and Etoposide, all of which have cardiotoxic effects. Myocarditis, a potentially threatening side effect following cancer therapy, can be accurately managed and diagnosed. CASE PRESENTATION: In the current study, we report the case of a 19-year-old female with a mass on the abdominal wall, diagnosed with ES/PNET. She was treated with the VAC/IE regimen. A month after the last session of chemotherapy, she experienced dyspnea. Upon evaluation, a high level of troponin and a low left ventricular ejection fraction (LVEF) were detected via transthoracic echocardiography. She was treated with anti-heart failure drugs, but the response was unsatisfactory. The possibility of Cancer therapy-related myocarditis was suspected, and cardiac magnetic resonance imaging (CMR) confirmed acute myocarditis. This patient exhibited a significant response to intravenous immunoglobulin (IVIG), with her LVEF improving from 30-35% to 50% within three months. CONCLUSION: In this case, based on negative tests and the absence of viral signs and symptoms, Cancer therapy-related myocarditis is highly suspected as the cause of myocarditis. This case underscores the importance of accurately utilizing CMR as a non-invasive method for diagnosing myocarditis. It effectively highlights the identification of reversible myocarditis with appropriate treatment and the notable response to IVIG, suggesting its potential as a favorable treatment for myocarditis in younger patients.
No takes yet. Share an insight, caveat, or question.
Emami et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: